This week BioCryst Pharmaceuticals, Inc. ($BCRX) announced FDA approval of ORLADEYO™ (berotralstat), the first oral and once-daily therapy to prevent seizures in hereditary angioedema patients. To top it all off, the company subsequently announced a $325 million financing together with Royalty Pharma and Athyrium Capital Management.
ORLADEYO™ offers patients with HAE the first orally administered non-steroidal seizure prevention option and represents an important and welcome step in making more treatment options available to physicians and patients. The new capital is intended to launch the product commercially and promote subsequent research. The launch of ORLADEYO™ in the United States and Europe is also an advantage.
The strength and potential of BCX9930
Long-term partners Royalty Pharma and Athyrium Capital Management allow BioCryst to fully invest in the launch of ORLADEYO™ and accelerate the development of BCX9930. The preclinical data of this oral Factor D inhibitor was promising after it showed complete in vitro blockade of both hemolysis of PNH erythrocytes and accumulation of C3 fragments on PNH erythrocytes. The monotherapy of BCX9930 thus demonstrates a high potential to inhibit both intravascular and extravascular hemolysis.
In addition, Athyrium Capital Management provides the following explanation. With a productive R&D capacity, long IP on the products and significant short term commercial opportunities, BioCryst represents the ideal profile Athyrium Capital Management is looking for new investments and partnerships.
It is claimed that the complement system could play an important role in many diseases characterized by an immune component. Think of: asthma, lupus, various forms of arthritis, autoimmune heart disease, multiple sclerosis and inflammatory bowel disease.
How the cake is divided
Royalty Pharma will provide BioCryst with an upfront cash payment of $125 million and will receive royalties of 8.75% on direct annual net sales of ORLADEYO™ up to $350 million, 2.75% on sales between $350 million and $550 million, no royalty on sales over $550 million, and a tiered percentage of sublicense revenue for ORLADEYO™ in certain territories. Royalty Pharma will receive a 1.0% royalty on global net sales of BCX9930, once this is approved.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.